Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company dedicated to developing off-the-shelf, genetically unmodified T cell therapies for infectious diseases, cancers, neurological disorders, and other large patient populations. The company leverages its proprietary ExacTcell platform, artificial intelligence initiatives, and disruptive business models to accelerate product development, improve health outcomes, and ensure patient accessibility. With a focus on affordability and innovation, Tevogen aims to transform personalized immunotherapies into accessible treatments worldwide.
Industries
Nr. of Employees
small (1-50)
Tevogen Bio
Products
Precision allogeneic CD8+ T-cell therapy platform
A platform for producing off-the-shelf, genetically unmodified CD8+ cytotoxic T-cell products targeting disease-relevant antigens presented on HLA molecules.
Investigational off-the-shelf cytotoxic T-cell therapy for acute high-risk viral infection
An investigational allogeneic cytotoxic T-cell therapy designed to recognize multiple viral protein targets with the intent to reduce viral load and symptoms in high-risk patients.
AI-based predictive target identification tool (in development)
A machine learning tool under development to predict immunologically active peptide–HLA complexes and T-cell receptor engagement to accelerate preclinical target discovery and candidate selection.
T-cell–focused vaccine concept (preclinical)
A vaccine approach aimed at eliciting or modulating T-cell responses; development supported by provisional patent activity.
Precision allogeneic CD8+ T-cell therapy platform
A platform for producing off-the-shelf, genetically unmodified CD8+ cytotoxic T-cell products targeting disease-relevant antigens presented on HLA molecules.
Investigational off-the-shelf cytotoxic T-cell therapy for acute high-risk viral infection
An investigational allogeneic cytotoxic T-cell therapy designed to recognize multiple viral protein targets with the intent to reduce viral load and symptoms in high-risk patients.
AI-based predictive target identification tool (in development)
A machine learning tool under development to predict immunologically active peptide–HLA complexes and T-cell receptor engagement to accelerate preclinical target discovery and candidate selection.
T-cell–focused vaccine concept (preclinical)
A vaccine approach aimed at eliciting or modulating T-cell responses; development supported by provisional patent activity.
Services
Design and execution of early-phase clinical studies including safety assessment, virologic and exploratory endpoints, and clinical monitoring.
Development and application of ML models to prioritize immunologic targets and predict receptor engagement to accelerate preclinical candidate selection, using cloud compute partnerships.
Technology transfer, process qualification planning, and engagement with facility providers to establish dedicated R&D and GMP manufacturing capacity for cell therapy production.
Design and execution of early-phase clinical studies including safety assessment, virologic and exploratory endpoints, and clinical monitoring.
Development and application of ML models to prioritize immunologic targets and predict receptor engagement to accelerate preclinical candidate selection, using cloud compute partnerships.
Technology transfer, process qualification planning, and engagement with facility providers to establish dedicated R&D and GMP manufacturing capacity for cell therapy production.
Expertise Areas
- Cell therapy preclinical and translational development
- Clinical trial management for cellular therapeutics
- Cell therapy process development and manufacturing scale-up
- AI-driven target identification and predictive modeling in immunology
Key Technologies
- Allogeneic CD8+ cytotoxic T-cell platforms
- Machine learning for HLA-peptide immunogenicity prediction
- T-cell receptor engagement prediction algorithms
- Cloud-based AI platforms for preclinical workflows
News & Updates
Tevogen Bio celebrated the commencement of its public trading by ringing the opening bell at Nasdaq in February 2024, marking a significant milestone in its growth and commitment to developing affordable, genetically unmodified T cell therapies.
Tevogen Bio is actively expanding its artificial intelligence efforts through Tevogen.AI, filing patents related to AI algorithms for immunological predictions, and emphasizing the importance of talent development in healthcare AI.
Tevogen Bio successfully listed on NASDAQ and began public trading in February 2024, a major milestone demonstrating its growth and market presence.
Tevogen Bio celebrated the commencement of its public trading by ringing the opening bell at Nasdaq in February 2024, marking a significant milestone in its growth and commitment to developing affordable, genetically unmodified T cell therapies.
Tevogen Bio is actively expanding its artificial intelligence efforts through Tevogen.AI, filing patents related to AI algorithms for immunological predictions, and emphasizing the importance of talent development in healthcare AI.
Tevogen Bio successfully listed on NASDAQ and began public trading in February 2024, a major milestone demonstrating its growth and market presence.